Back to search results

Comparing Over-the-Counter Pain Medicines for Crohn's Disease and Period Pain

This study, called AVID-CD, is a pilot study to help researchers prepare for a larger study. It will compare two common pain medications, acetaminophen (Tylenol) and ibuprofen (Advil, Motrin), for treating period cramps in women who also have Crohn's disease. The main goal is to understand how easy or difficult it is to run such a study. Researchers will look at how many people are interested, how many join, and how well participants follow the study instructions, like taking medication and completing surveys. You may be able to join if you are a woman between 18 and 44 years old, have Crohn's disease that is currently in remission, and experience regular period pain. The study is currently unclear about its recruitment status.

Study design
This is an interventional study with 24 planned participants. It is designed to prepare for a larger study comparing acetaminophen and ibuprofen.
What's involved
Participants will take either acetaminophen or ibuprofen for three days during two of four menstrual cycles. They will also complete study activities like submitting samples and filling out surveys.
Compensation
Not stated in the trial record.
Follow-up
Participants will be followed from enrollment to study completion, which is approximately 2.5 years.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07337902

Comparing Over the Counter Pain Medicines for Discomfort in Crohn's Disease (AVID-CD)

Recruiting
NAAges 18–44InterventionalTreatment
University of North Carolina, Chapel Hill
~24 participants
Updated 2026-07-14 on ClinicalTrials.gov
What's tested:AcetaminophenIbuprofen

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Proportion of Participants Who Express Interest in the Study Out of Those Contacted
Measured over from first contact to informed consent, up to 2 years
+2 more outcomes measured

Conditions

Crohn's Disease (CD)
Dysmenorrhea Primary

Explore related trials

Crohn DiseaseDysmenorrhea

Where it's being run

1 sites across 1 states
North Carolina1

Study leadership

  • Erica J Brenner, MD, MSCR · PRINCIPAL_INVESTIGATOR · University of North Carolina, Chapel Hill

Who to contact

Rachel Cooke, MS
[email protected]
919-964-2141
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Ages 18-44 years
Assigned female at birth
Crohn's Disease (CD) diagnosis
In stable clinical remission from CD, defined as a short Crohn's Disease Activity Index (CDAI; See Table 3) \<150 without use of corticosteroids
Self-reported primary dysmenorrhea
Regular menstrual cycles occurring every 23-35 days
Using an appropriate contraceptive method or abstinence

Exclusion

Any of the following conditions: endometriosis, adenomyosis, polycystic ovarian syndrome, endometrial fibroids/polyps, chronic pelvic inflammatory disease, a history of pelvic surgery including hysterectomy, any other pathological pelvic conditions, or current pregnancy
Plans to become pregnant during the study period
Use of an oral contraceptive for less than 3 months, on an unstable oral contraceptive dose within the last 3 months, switched from one oral contraceptive to another within the last 3 months or intend to do so during the course of the trial
Taking hormone therapy including estrogen or progesterone that is not part of a hormonal contraceptive
Known hypersensitivity or contraindication to ibuprofen or acetaminophen
Inability to complete REDCap questionnaires (including confusion despite training and/or lack of smart phone and/or computer access).
Not able to speak and read English language.

What this trial measures

  • Proportion of Participants Who Express Interest in the Study Out of Those Contactedfrom first contact to informed consent, up to 2 years

    Accrual will be determined as the proportion of participants who express interest in the study out of those contacted

  • Proportion of participants who enroll out of those who expressed interest in the studyfrom first contact to informed consent, up to 2 years

    Accrual will be determined by the proportion of participants who enroll out of those who expressed interest in the study

  • Proportion of participants who meet the minimum adherence needed to contribute effectively to a subsequent study out of those randomizedenrollment to completion of study, approximately 2.5 years

    Protocol Adherence will be determined by the proportion of participants who meet the minimum adherence needed to contribute effectively to a subsequent study out of those randomized